Prostate‐specific antigen relapse‐free survival in patients with localized prostate cancer treated by brachytherapy

Abstract

The overall relapse-free survival for all patients was 75%; the initial PSA, Gleason score and risk group were significant factors predicting the outcome. Increasing clinical experience was associated with a better outcome but neoadjuvant hormone therapy had no effect.